The use of GPR120 agonists may be beneficial in the treatment of metabolic diseases, especially those involving IR and impaired glucose tolerance, as well as chronic low-grade inflammation, which involves mainly adipose tissue in obese individuals [99,226,227,228]. Here, FFAR4 is linked to metabolic disease.